Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bruce Booth sold 285,684 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $121.86, for a total value of $34,813,452.24. Following the sale, the director directly owned 529,718 shares in the company, valued at approximately $64,551,435.48. This represents a 35.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bruce Booth also recently made the following trade(s):
- On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The stock was sold at an average price of $115.39, for a total transaction of $30,305,683.43.
- On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The shares were sold at an average price of $100.51, for a total value of $13,540,707.20.
- On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.98, for a total value of $140,771.84.
- On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total value of $24,268,431.60.
- On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.01, for a total transaction of $10,471,246.56.
- On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.38, for a total value of $9,496,316.98.
- On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total value of $1,056,455.18.
- On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The shares were sold at an average price of $103.75, for a total transaction of $3,299,042.50.
- On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.08, for a total value of $9,008.00.
- On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.96, for a total value of $530,764.00.
Kymera Therapeutics Stock Performance
NASDAQ KYMR traded up $16.59 on Thursday, reaching $116.46. The company’s stock had a trading volume of 3,915,007 shares, compared to its average volume of 826,395. The stock has a market cap of $9.58 billion, a PE ratio of -32.62 and a beta of 2.02. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $130.05. The firm’s 50 day moving average is $84.43 and its two-hundred day moving average is $82.12.
Analyst Ratings Changes
KYMR has been the topic of a number of research analyst reports. Canaccord Genuity Group assumed coverage on Kymera Therapeutics in a report on Wednesday, May 6th. They set a “buy” rating and a $106.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 target price on the stock. Morgan Stanley reissued an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Piper Sandler upped their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, Stephens increased their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $117.14.
View Our Latest Stock Report on Kymera Therapeutics
Institutional Trading of Kymera Therapeutics
Several institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after acquiring an additional 1,833 shares during the period. Millennium Management LLC raised its position in Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after buying an additional 491,737 shares in the last quarter. Invesco Ltd. boosted its position in Kymera Therapeutics by 13.8% in the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock valued at $2,090,000 after buying an additional 5,809 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at $265,000.
Trending Headlines about Kymera Therapeutics
Here are the key news stories impacting Kymera Therapeutics this week:
- Positive Sentiment: Kymera announced that enrollment in its Phase 2b BROADEN2 trial of KT-621 for moderate to severe atopic dermatitis was completed nearly six months ahead of schedule, with topline data expected by year-end 2026. The accelerated timeline also supports the company’s broader development plans for KT-621, including a planned Phase 3 start by mid-2027. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
- Positive Sentiment: BTIG Research reaffirmed its buy rating and set a $134 price target, implying additional upside if the clinical program continues to progress. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
- Neutral Sentiment: The company also announced Felix J. Baker, Ph.D. as chairman of the board, a leadership change that may help support oversight but is less likely to move the stock on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
- Negative Sentiment: Insider Noah Goodman sold 5,000 shares at $114 each, which can sometimes be viewed as a cautious signal, though the sale was relatively small versus his remaining holdings. Article: Insider transaction filing
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company’s pipeline emphasizes immunology and oncology.
Featured Stories
- Five stocks we like better than Kymera Therapeutics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
